Feasible to prescribe ART to emergency department patients with suspected acute HIV infection
New integrase inhibitor bictegravir looks promising in early studies
Atripla three times weekly maintains HIV viral suppression for 24 weeks
PRO 140 antibody injections maintain viral suppression in phase 2 study
Less frequent CD4 and viral load monitoring safe for people doing well on ART
Big increases in proportion of HIV-positive people in US treated with ART and with viral suppression
Sub-type C infection does not increase the risk of virologic failure when people are taking tenofovir-containing first-line ART
Two million people with HIV started treatment in 2015
